Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Herzyk, D. J.
Right arrow Articles by Wier, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herzyk, D. J.
Right arrow Articles by Wier, P. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Preclinical Safety of Recombinant Human Interleukin-18

Danuta J. Herzyk

Department of Safety Assessment, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA, danuta.j.herzyk{at}gsk.com

Peter J. Bugelski

Department of Safety Assessment, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA, Presently at J&J/Centocor, Inc., Malvern, Pennsylvania, USA

Timothy K. Hart

Department of Safety Assessment, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA

Patrick J. Wier

Department of Safety Assessment, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA

Recombinant human interleukin-18 (rHuIL-18) is currently in clinical trials for treatment of cancer. This report presents results of preclinical toxicity studies with rHuIL-18 in cynomolgus monkeys and recombinant murine IL-18 (rMuIL-18) in mice. The rHuIL-18 was administered intravenously in 1 or 2 different 5-day cycles at doses 0.3 to 75 mg/kg/day in monkeys. Decreases in red cell mass, neutrophil, and platelet counts, increases in monocyte and large unstained cell counts, and lymphoid hyperplasia in spleen and lymph nodes were mild, reversible, and likely related to the pharmacologic activity of IL-18. The only toxic effect was protein cast nephropathy, secondary to coprecipitation of administered IL-18 and Tamm-Horsfall protein in the distal nephron, that only occurred at 75 mg/kg/day. Other adverse effects of rHuIL-18 were related to strong immunogenicity in monkeys and were manifest only during a second dosing cycle. The rMuIL-18, at similar dosing levels and cycles in mice, resulted in reduced red cell mass, increased white blood cell counts, spleen and lymph node hyperplasia, and mild, reversible changes in intestine, liver, and lungs. Protein cast nephropathy occurred in mice at doses ≥30 mg/kg/day. In conclusion, preclinical safety studies showed that rIL-18 was well tolerated at pharmacologically active doses in both monkeys and mice.

Key Words: IL-18 • nephrotoxicity • monkeys • mice.

Toxicologic Pathology, Vol. 31, No. 5, 554-561 (2003)
DOI: 10.1080/01926230390226681
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Vet PatholHome page
R. E. Guzman, K. Datta, and N. K. Khan
Obstructive Protein Cast Nephropathy in Cynomolgus Monkeys Treated with Small Organic Molecules
Vet. Pathol., November 1, 2008; 45(6): 945 - 948.
[Abstract] [Full Text] [PDF]